Benzinga - by Maureen Meehan, Benzinga Editor.
In the hallowed chambers of the Senate Finance Committee on Thursday, a testy exchange took place between Sen. John Cornyn (R-Texas) and Health and Human Services (HHS) Secretary Xavier Becerra. The bone of contention was the proposed rescheduling of marijuana under federal law.
Cornyn grilled Becerra on the HSS's August 2023 recommendation to the Drug Enforcement Administration (DEA) to reclassify marijuana from a Schedule I to a Schedule III substance, reported Marijuana Moment.
Cornyn seemed to take issue with the thoroughness of the scientific scrutiny and research into cannabis, which was directed by President Joe Biden and undertaken by the Food and Drug Administration (FDA). Cornyn hinted at a departure from previous approaches to scheduling drugs.
In response, Becerra pointed to a comprehensive 252-page analysis asserting that cannabis "has a currently accepted medical use in treatment in the United States," and the "potential for abuse less than the drugs or other substances in Schedules I and II.”
The HHS secretary even pointed to Cornyn’s state of Texas and its tentative steps toward accepting medical marijuana. "What we're doing is simply reflecting what the science is showing," Becerra said.
Surely you will want to hear more on this topic and how it will affect the cannabis industry in many ways. If that’s the case, then you must join us at the upcoming Benzinga Cannabis Capital Conference in Florida.
Cornyn, who echoed the arguments widely disseminated by the prohibitionist group Smart Approaches to Marijuana, took issue with the HHS’s lenient stance. He questioned whether the review examined the health impacts of marijuana use on adolescent brains and pregnant women.
Despite this, Becerra stood firm, seemingly confident in the FDA’s recommendations. "As you know, throughout the country, many states have moved much farther than the federal government has."
Becerra said he didn't want to speak for the FDA in that the agency's scientists had conducted the review "independently" of the HHS's leadership, but he insisted "the rigorous work that was done to come to these conclusions was based on the science and the evidence they had before them."
As the discussion moved toward the DEA’s impending decision, Becerra deflected questions about timing, humorously suggesting that inquisitive parties should go and “knock on DEA’s door.”
Join us for more policy discussions at the upcoming Benzinga Cannabis Capital Conference in Florida at the new Hollywood venue on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn, and grow.
Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world. Get your tickets now on bzcannabis.com – Prices will increase very soon!
Photo: Xavier Becerra via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.